Jan 28 (Reuters) - Bausch Health Companies Inc BHC.TO :
* BAUSCH HEALTH AND CLEARSIDE BIOMEDICAL ANNOUNCE PUBLICATION OF PIVOTAL PHASE 3 DATA ON XIPERETM (TRIAMCINOLONE ACETONIDE SUPRACHOROIDAL INJECTABLE SUSPENSION) IN OPHTHALMOLOGY
* CLEARSIDE BIOMEDICAL - DATA SHOWED THAT PATIENTS WITH NONINFECTIOUS UVEITIS IN XIPERE STUDY ARM SAW CLINICALLY SIGNIFICANT IMPROVEMENT IN VISION
* CLEARSIDE BIOMEDICAL - NO SERIOUS ADVERSE EVENTS CONSIDERED BY INVESTIGATORS RELATED TO TREATMENT WERE REPORTED IN STUDY